XTL Biopharmaceuticals Ltd. XTLB
2.20
(0.21)
(8.71%)
as of 25 Sep
- Market cap
- $9.7M
- P/E
- 0.0×
Follow XTLB
| Jun '25 | Sep '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
| Current Ratio | 0.70 | 0.81 | 11.43 | 9.93 |
+8 more quarters Free account |
| Net Debt/EBITDA | 0.00 | 0.00 | 13.37 | 0.00 | |
| Debt/Assets | 12.04% | 1.81% | 0.00% | 0.00% | |
| Debt/Equity | (1.83) | 0.03 | 0.00 | 0.00 | |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF/Net income | — | — | 0.00 | — | |
| Interest Coverage | — | — | 0.00 | — | |
| Research and Development Expense of Revenue | — | — | 0.00% | — | |
| Selling, General and Administrative Expense of Revenue | — | — | 0.00% | — | |
| Intangible Assets out of Total Assets | 0.00 | 0.76 | 0.13 | 0.16 | |
| Free Cash Flow per Share | — | — | 0.00 | — | |
| Cash per Share | 0.00 | 0.00 | 1.72 | 0.00 | |
| Shareholders Equity per Share | 0.00 | 0.00 | 1.99 | 0.00 | |
| Interest Debt per Share | 0.00 | 0.00 | 0.00 | — | |
| Book value per Share | 0.00 | 0.00 | 1.99 | 0.00 | |
| Free Cash Flow | — | — | — | — | |
| Working Capital | (0.23) | (0.48) | 2.33 | 1.84 | |
| Net Current Asset Value | (0.23) | (1.58) | 2.33 | 1.84 | |
| Other line items | |||||
| Quick Ratio | 0.46 | 0.75 | 11.16 | 9.74 | |
| Revenue per Share | — | — | 0.00 | — | |
| Operating CF per Share | — | — | 0.00 | — | |
| Capex per Share | — | — | 0.00 | — | |
| Average Receivables | 0.17 | 0.17 | 0.19 | — | |
| Average Payables | 0.40 | 0.36 | 0.23 | 0.20 | |
| Average Assets | 1.69 | 6.07 | 3.13 | 3.31 | |
| Average Common Equity | 1.23 | 4.21 | 2.89 | 3.11 | |
| Net Profit Margin | — | — | 0.00% | — |
Columns are period end dates